97 related articles for article (PubMed ID: 25860233)
1. Economic impact of disease progression following front-line therapy in classical Hodgkin lymphoma.
Yasenchak CA; Tseng WY; Yap M; Rembert D; Patt DA
Leuk Lymphoma; 2015; 56(11):3143-9. PubMed ID: 25860233
[TBL] [Abstract][Full Text] [Related]
2. Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma.
Aly A; Johnson C; Yang S; Botteman MF; Rao S; Hussain A
J Med Econ; 2019 Jul; 22(7):662-670. PubMed ID: 30836812
[No Abstract] [Full Text] [Related]
3. Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy.
Martínez C; Díaz-López A; Rodriguez-Calvillo M; García-Sanz R; Terol MJ; Pérez-Ceballos E; Jiménez MJ; Cantalapiedra A; Domingo-Domenech E; Rodriguez MJ; Sampol A; Espeso M; López FJ; Briones J; García JF; Sureda A;
Br J Haematol; 2016 Sep; 174(6):859-67. PubMed ID: 27185197
[TBL] [Abstract][Full Text] [Related]
4. Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma.
Sinha R; Shenoy PJ; King N; Lechowicz MJ; Bumpers K; Hutcherson D; Arellano M; Langston A; Kaufman J; Heffner LT; Waller EK; Nooka A; Flowers CR; Lonial S
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):657-63. PubMed ID: 24094894
[TBL] [Abstract][Full Text] [Related]
5. Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group.
Sasse S; Alram M; Müller H; Smardová L; Metzner B; Doehner H; Fischer T; Niederwieser DW; Schmitz N; Schäfer-Eckart K; Raemaekers JM; Schmalz O; Tresckow BV; Engert A; Borchmann P
Leuk Lymphoma; 2016 May; 57(5):1067-73. PubMed ID: 26693800
[TBL] [Abstract][Full Text] [Related]
6. Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation.
Shah GL; Yahalom J; Matasar MJ; Verwys SL; Goldman DA; Bantilan KS; Zhang Z; McCall SJ; Moskowitz AJ; Moskowitz CH
Br J Haematol; 2016 Nov; 175(3):440-447. PubMed ID: 27377168
[TBL] [Abstract][Full Text] [Related]
7. Impact of time from diagnosis to initiation of curative-intent chemotherapy on clinical outcomes in patients with classical Hodgkin lymphoma.
Brooks EG; Connors JM; Sehn LH; Gascoyne RD; Savage KJ; Shenkier TN; Klasa R; Gerrie AS; Skinnider B; Slack GW; Villa D
Leuk Lymphoma; 2016; 57(4):872-9. PubMed ID: 26325236
[TBL] [Abstract][Full Text] [Related]
8. Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting.
Eyre TA; Phillips EH; Linton KM; Arumainathan A; Kassam S; Gibb A; Allibone S; Radford J; Peggs K; Burton C; Stewart G; LeDieu R; Booth C; Osborne WL; Miall F; Eyre DW; Ardeshna KM; Collins GP
Br J Haematol; 2017 Nov; 179(3):471-479. PubMed ID: 28857136
[TBL] [Abstract][Full Text] [Related]
9. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
Jalali A; Ha FJ; Chong G; Grigg A; Mckendrick J; Schwarer AP; Doig R; Hamid A; Hawkes EA
Ann Hematol; 2016 Apr; 95(5):809-16. PubMed ID: 26878861
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns and economic burden among newly diagnosed cervical and endometrial cancer patients.
Nwankwo C; Shah R; Shah A; Corman S; Kebede N
Future Oncol; 2022 Mar; 18(8):965-977. PubMed ID: 35105169
[No Abstract] [Full Text] [Related]
11. Young adults diagnosed with Hodgkin lymphoma are at risk of relapsing late: a comprehensive analysis of late relapse in Hodgkin lymphoma.
Pinczés L; Miltényi Z; Illés Á
J Cancer Res Clin Oncol; 2018 May; 144(5):935-943. PubMed ID: 29468437
[TBL] [Abstract][Full Text] [Related]
12. Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience.
Viviani S; Di Nicola M; Bonfante V; Di Stasi A; Carlo-Stella C; Matteucci P; Magni M; Devizzi L; Valagussa P; Gianni AM
Leuk Lymphoma; 2010 Jul; 51(7):1251-9. PubMed ID: 20528244
[TBL] [Abstract][Full Text] [Related]
13. [Therapy for patients with primary refractory and relapsed Hodgkin-lymphoma--our experience].
Miltényi Z; Simon Z; Páyer E; Váróczy L; Gergely L; Illés A
Orv Hetil; 2010 Jan; 151(5):172-8. PubMed ID: 20083465
[TBL] [Abstract][Full Text] [Related]
14. Therapies for relapsed Hodgkin lymphoma: transplant and non-transplant approaches including immunotherapy.
Bartlett NL
Hematology Am Soc Hematol Educ Program; 2005; ():245-51. PubMed ID: 16304388
[TBL] [Abstract][Full Text] [Related]
15. Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP).
Pavone V; Mele A; Carlino D; Specchia G; Gaudio F; Perrone T; Mazza P; Palazzo G; Guarini A; Loseto G; Eleonora P; Cascavilla N; Scalzulli P; Melpignano A; Quintana G; Di Renzo N; Tarantini G; Capalbo S
Ann Hematol; 2018 Oct; 97(10):1817-1824. PubMed ID: 30054707
[TBL] [Abstract][Full Text] [Related]
16. Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: A retrospective cohort study.
Szabo SM; Hirji I; Johnston KM; Juarez-Garcia A; Connors JM
PLoS One; 2017; 12(10):e0180261. PubMed ID: 28991893
[TBL] [Abstract][Full Text] [Related]
17. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma.
Pinnix CC; Smith GL; Milgrom S; Osborne EM; Reddy JP; Akhtari M; Reed V; Arzu I; Allen PK; Wogan CF; Fanale MA; Oki Y; Turturro F; Romaguera J; Fayad L; Fowler N; Westin J; Nastoupil L; Hagemeister FB; Rodriguez MA; Ahmed S; Nieto Y; Dabaja B
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):175-82. PubMed ID: 25863764
[TBL] [Abstract][Full Text] [Related]
18. Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL.
Moore S; Kayani I; Peggs K; Qian W; Lowry L; Thomson K; Linch DC; Ardeshna K
Br J Haematol; 2012 Jun; 157(5):543-52. PubMed ID: 22429186
[TBL] [Abstract][Full Text] [Related]
19. A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.
Milgrom SA; Jauhari S; Plastaras JP; Nieto Y; Dabaja BS; Pinnix CC; Smith GL; Allen PK; Lukens JN; Maity A; Oki Y; Fanale MA; Nasta SD
Cancer; 2017 Apr; 123(8):1363-1371. PubMed ID: 27984652
[TBL] [Abstract][Full Text] [Related]
20. Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: a population-based analysis of the Austrian Cooperative Study Group.
Attarbaschi A; Dworzak M; Steiner M; Urban C; Fink FM; Reiter A; Gadner H; Mann G
Pediatr Blood Cancer; 2005 Jan; 44(1):70-6. PubMed ID: 15368550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
